

PD-168077 maleate

Chemical Properties


CAS No. : 630117-19-0

Formula: C₂₄H₂₆N₄O₅

Molecular Weight: 450.49

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

| | |
|---------------|---|
| Description | PD-168077 maleate is a selective agonist of the dopamine D4 receptor (K _i : 9 nM). |
| Targets(IC50) | Dopamine Receptor |
| In vivo | PD-168077, a selective D4 dopamine receptor agonist, injected into the paraventricular nucleus of the hypothalamus on penile erection was studied in male rats. PD-168077 (1-200 ng) induced penile erection in a dose-dependent manner. The minimal effective dose was 50 ng, while the maximal response was found with 200 ng of the compound, which increased penile erection episodes from 0.3+/-0.03 to 1.7+/-0.21. The proerectile effect of PD-168077 was reduced almost completely by L-745,870 (3-(4-[chlorophenyl] piperazin-1-yl)-methyl-1H-pyrrolo[2,3-B]pyridine trihydrochloride), a selective D4 dopamine receptor antagonist, (1 microg) given into the paraventricular nucleus before the D4 dopamine agonist, and by other nonselective dopamine receptor antagonists, such as haloperidol (1 microg) and clozapine (1 microg), which block all dopamine receptor subtypes. The pro-erectile effect of PD-168077 was also reduced by the NO synthase inhibitor NG-nitro-L-arginine methylester (25 microg), but not by the oxytocin receptor antagonist d(CH ₂) ₅ Tyr(Me) ₂ -Orn ₈ -vasotocin (1 microg), when given into the paraventricular nucleus. In spite of its inability to prevent the pro-erectile effect of PD-168077 when given in the paraventricular nucleus, d(CH ₂) ₅ Tyr(Me) ₂ -Orn ₈ -vasotocin (1 microg) reduced almost completely PD-168077-induced penile erection when given into the lateral ventricles[1]. |

Solubility Information

| | |
|---------------------|---|
| Solubility | DMSO: 150 mg/mL (332.97 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble) |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (8.88 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|------------|------------|-------------|
| 1 mM | 2.2198 mL | 11.099 mL | 22.1981 mL |
| 5 mM | 0.444 mL | 2.2198 mL | 4.4396 mL |
| 10 mM | 0.222 mL | 1.1099 mL | 2.2198 mL |
| 50 mM | 0.0444 mL | 0.222 mL | 0.444 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Maria, Rosaria, Melis, et al. PD-168077, a selective dopamine D4 receptor agonist, induces penile erection when injected into the paraventricular nucleus of male rats[J]. *Neuroscience Letters*, 2005.

Clifford JJ, et al. Topographically based search for an "Ethogram" among a series of novel D(4) dopamine receptor agonists and antagonists. *Neuropsychopharmacology*. 2000 May;22(5):538-44.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481